GANX
Gain Therapeutics, Inc.
There isn't enough reported data to score GANX yet.
GANX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
GANX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
GANX PE Valuation
GANX has no meaningful PE right now: it lost money over the past year.
GANX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect GANX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
GANX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.42 | +$0.16 |
| Q2 2026 | -$0.50 | +$0.10 |
| Q1 2026 | -$0.58 | +$0.25 |
| Q4 2025 | -$0.61 | +$0.28 |
| Q3 2025 | -$0.58 | +$0.52 |
| Q2 2025 | -$0.60 | +$0.70 |
| Q1 2025 | -$0.83 | +$0.67 |
| Q4 2024 | -$0.89 | +$0.82 |
GANX is still losing money, but far less than before: $0.42 per share over the past year, against $1.82 at its worst in mid-2023.
GANX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2023 | $55.2K | +23% |
| Q2 2022 | $95.1K | +6.6% |
| Q1 2022 | $45K | +754% |
| Q4 2021 | $43.2K | +373% |
| Q3 2021 | $27.3K | +308% |
| Q2 2021 | $89.2K | +1299% |
| Q1 2021 | $5.3K | -21% |
GANX's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2023 | -9478% | -2171 points |
| Q2 2022 | -5443% | -1502 points |
| Q1 2022 | -7307% | +39513 points |
| Q4 2021 | -7426% | +10252 points |
| Q3 2021 | -16953% | -4721 points |
| Q2 2021 | -3941% | +4414 points |
| Q1 2021 | -46819% | -39143 points |
| Q4 2020 | -17678% | N/A |
GANX's operating margin was −9478% last quarter, up 7476 points from the same quarter a year ago.
GANX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.7M | -$906K |
| Q4 2024 | -$3.5M | +$2.2M |
| Q3 2024 | -$6.1M | -$2.1M |
| Q4 2023 | -$5.7M | -$1.7M |
| Q3 2023 | -$4M | -$621.1K |
| Q2 2023 | -$5M | +$70.6K |
| Q1 2023 | -$4.2M | -$1.8M |
| Q4 2022 | -$3.9M | +$243.5K |
GANX has burned cash in almost every quarter: −$16M over the past year, against −$19M the year before.
GANX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +892K shares |
| 1 year | +44% | +13.4M shares |
| 3 years | +253% | +31.4M shares |
| 5 years | +269% | +31.9M shares |
| Available history | +332% | +33.6M shares |
GANX has 44M diluted shares, up 44% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
GANX Net Leverage
GANX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
GANX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.2 | Neutral |
| Stochastic | 5.9 | Oversold |
GANX's weekly RSI is 33 (neutral) and its Stochastic is 6 (oversold).
GANX PE vs Healthcare Sector
GANX has no meaningful PE right now: it lost money over the past year.
GANX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.36 | 21% below |
| 20 week MA | $1.64 | 34% below |
| 50 week MA | $1.99 | 46% below |
| 100 week MA | $1.99 | 46% below |
| 200 week MA | $2.60 | 58% below |
GANX is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
GANX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $12.2 | $5.70 | -53% |
| 2022 | $5.70 | $3.15 | -45% |
| 2023 | $3.15 | $3.27 | +3.8% |
| 2024 | $3.27 | $1.76 | -46% |
| 2025 | $1.76 | $3.15 | +79% |
| 2026 YTD | $3.15 | $1.08 | -66% |
GANX has finished lower in three of the last five years. It's down 66% so far in 2026.